Senesco Technologies (ELOX)
(Delayed Data from OTC)
$0.86 USD
-0.04 (-4.61%)
Updated May 15, 2024 09:52 AM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELOX 0.86 -0.04(-4.61%)
Will ELOX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ELOX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELOX
Senesco Technologies Inc. (ELOX) Reports Q1 Loss, Lags Revenue Estimates
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
ELOX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Senesco Technologies Inc. (ELOX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
Other News for ELOX
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Eloxx Pharmaceuticals provides ELX-02, ZKN-013 program updates
Eloxx Pharmaceuticals treatment of Alport Syndrome granted FDA orphan status
Eloxx Pharmaceuticals CEO Stock Option Repricing Initiative
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases